- Home
- AORT vs PTA Comparison
AORT vs PTA Comparison
Compare AORT & PTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AORT
- PTA
- Stock Information
- Founded
- AORT 1984
- PTA 2020
- Country
- AORT United States
- PTA United States
- Employees
- AORT 1500
- PTA N/A
- Industry
- AORT Medical/Dental Instruments
- PTA Trusts Except Educational Religious and Charitable
- Sector
- AORT Health Care
- PTA Finance
- Exchange
- AORT Nasdaq
- PTA Nasdaq
- Market Cap
- AORT 1.2B
- PTA 1.1B
- IPO Year
- AORT 1993
- PTA N/A
- Fundamental
- Price
- AORT $28.30
- PTA $19.82
- Analyst Decision
- AORT Strong Buy
- PTA
- Analyst Count
- AORT 5
- PTA 0
- Target Price
- AORT $31.80
- PTA N/A
- AVG Volume (30 Days)
- AORT 303.7K
- PTA 159.2K
- Earning Date
- AORT 02-24-2025
- PTA 01-01-0001
- Dividend Yield
- AORT N/A
- PTA 8.31%
- EPS Growth
- AORT N/A
- PTA N/A
- EPS
- AORT N/A
- PTA N/A
- Revenue
- AORT $384,899,000.00
- PTA N/A
- Revenue This Year
- AORT $12.95
- PTA N/A
- Revenue Next Year
- AORT $9.76
- PTA N/A
- P/E Ratio
- AORT N/A
- PTA N/A
- Revenue Growth
- AORT 13.29
- PTA N/A
- 52 Week Low
- AORT $18.38
- PTA $15.84
- 52 Week High
- AORT $32.33
- PTA $19.67
- Technical
- Relative Strength Index (RSI)
- AORT 33.50
- PTA 49.41
- Support Level
- AORT $29.31
- PTA $19.74
- Resistance Level
- AORT $30.40
- PTA $19.99
- Average True Range (ATR)
- AORT 0.89
- PTA 0.20
- MACD
- AORT -0.33
- PTA -0.03
- Stochastic Oscillator
- AORT 5.65
- PTA 12.31
About AORT Artivion Inc.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.
About PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its primary investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.